Oncology products achieved operational sales growth of 16.1% as compared to the same period a year ago
Contributors to the growth were: DARZALEX driven by strong share gains and market growth, CARVYKTI driven by continued share gains and site expansion, TECVAYLI driven by launch uptake and share gains from the U.S. TECVAYLI + DARZALEX FASPRO approval, TALVEY driven by share gains from expansion in the community setting, RYBREVANT/LAZCLUZE driven by launch uptake and share gains
In the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%
Worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational increase of 6.0%
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedsix sentences · whole, uncut
the claims it rests on
“Oncology products achieved operational sales growth of 16.1% as compared to the same period a year ago”
“Contributors to the growth were: DARZALEX driven by strong share gains and market growth, CARVYKTI driven by continued share gains and site expansion, TECVAYLI driven by launch uptake and share gains from the U.S. TECVAYLI + DARZALEX FASPRO approval, TALVEY driven by share gains from expansion in the community setting, RYBREVANT/LAZCLUZE driven by launch uptake and share gains”
“In the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%”
“Worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational increase of 6.0%”
what it was checked against
oncology growth contributors
“Contributors to the growth were: DARZALEX (daratumumab) driven by strong share gains and market growth, CARVYKTI (ciltacabtagene autoleucel) driven by continued share gains and site expansion, TECVAYLI (teclistamab-cqyv) driven by launch uptake and share gains from the U.S. TECVAYLI + DARZALEX FASPRO approval and expansion in the community setting, TALVEY (talquetamab-tgvs) driven by share gains from expansion in the community setting, RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) driven by launch uptake and share gains and ERLEADA (apalutamide) due to continued share gains and market growth partially offset by unfavorable patient mix and inventory dynamics.”
worldwide sales and growth figures
“For the fiscal six months of 2026, worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational* increase of 6.0% as compared to 2025 fiscal six months sales of $45.6 billion.”